Introduction
============

Gestational diabetes mellitus (GDM) is a prevalent disorder, resulting in more than 200,000 cases annually ([@B1]). It increases the risk of maternal problems, such as gestational hypertension, preeclampsia and cesarean section rate ([@B2], [@B3]). GDM can also increases fetal complications including hyperinsulinemia, macrosomia (often defined as a baby weighing more than 4000 grams), and consequently delivery complications, such as shoulder dystocia. The neonate is more likely to require admission to NICU or to experience respiratory distress syndrome, and metabolic complications, including hyper-bilirubinemia and hypoglycemia ([@B4]). The severity of adverse outcome depends on the time of GDM diagnosis and glycemic control. In fact, a linear correlation has been seen between maternal blood glucose level and various neonatal complications ([@B5]). Despite the well-established complications related to GDM, there is still substantial argument about its diagnosis ([@B6], [@B7]). According to the current revised version of guidelines published in 2013, an increase in the GDM incidence was detected ([@B5]). Traditional guidelines recommend that the OGTT (oral glucose tolerant test) containing 75g oral glucose at 24-28 weeks of gestation is a test for GDM diagnosis. It is a time-consuming and invasive method which is done for fasting pregnant women. In addition to these difficulties, there is a considerable inconsistency in the OGTT cut-offs for the GDM diagnosis ([@B3], [@B8]). The American Diabetic Association (ADA) and World Health Organization proposed that HbA1c test should be used for the diagnoses of type 2 diabetes, but not for GDM ([@B9], [@B10]). Over the erythrocyte life span, plasma glucose irreversibly is bound to hemoglobin (Hb) and determines the HbA1c level. It is a non-fasting blood test and reflects glucose levels over the last 3 month. It is shown that compared to glucose test, HbA1c has more reliability with less than 6% inter-laboratory variation. HbA1c has also better standardization between assays, as well as less pre-analytical and intra-individual variations ([@B11], [@B12]).

Due to the difficulties in OGTT method, as well as various cut-offs for HbA1c in different populations (because of difference in races and screening criteria) ([@B13]-[@B17]), newer acceptable and accessible tests are needed in each population. The aim of the present study is to assess the optimal cut-off value of HbA1c, in order to be used as a potential substitute for OGTT, in GDM screening for Iranian population.

Materials and methods
=====================

The present case-control study was approved by the ethics committee of Metabolic Research Center at Zanjan University of Medical Sciences. It was performed in accordance with ethical standards, laid down in the 1964 Declaration of Helsinki, and its later amendments or comparable ethical standards. The study was carried between June 2015 and March 2016. Pregnant women, without previous history of GDM or DM, attending the Valie-Asr Hospital to perform OGTT at the 24-28 week of pregnancy, were invited to participate in this study. Totally 200 GDM pregnant women who were diagnosed according to ADA/WHO 2013 criteria (fasting, 1 h and 2 h blood glucose more than 92 mg/dl, 180 mg/dl and 153 mg/dl) were selected as study cases, and 200 non GDM women were recruited for the control group ([@B9], [@B10]). All subjects provided their signed consent before the study enrollment. Demographic data including age of participants, gestational age, obstetric history, smoking, family history of chronic diseases such as type 2 diabetes, cardiovascular disease, hypertension, and history of high risk pregnancies were recorded. Patients with abnormal thyroid hormone concentration, anemia, presence of hemoglobinopathy, intake of supplements and/or medications that could affect body weight and/or energy expenditure, having a prescribed diet for weight control, smoking, diagnosis of chronic diseases including inflammatory diseases, heart, chronic liver and renal failure, cancer, acute myocardial infarction, diabetes, stroke, or serious injuries, and any other conditions that were not suitable for the trial as evaluated by the physician, were excluded from the study. Body weight and height were taken by using a calibrated Seca scale (to the nearest 100 grams) and a wall-mounted Seca scale (to the nearest 0.5 cm). BMI (Body Mass Index) was calculated according to the formula: BMI = weight/ height^2^ (kg/m^2^). Blood samples for all subjects were taken from the antecubital vein after 10-12 hour of fasting, and between 0700 and 0800 AM for biochemical measurements. Fasting, 1hour and 2 hour blood glucose were measured by an enzymatic method (Pars Azmoon Co. kit, Tehran, Iran) using Liasys autoanalyzer. Serum levels of HbA1c were measured by HPLC method (KNAUER, Germany, ser.No: 211133).

***Statistical analysis:***All data were expressed by means ± SD. P \< 0.05 was considered significant. IBM SPSS Statistics software (version 18; IBM Corp) was used for data analysis. Normal distribution of the variables was checked by Kolmogorov Smirnov Test**.**Normal distributed data were compared by the independent sample t-test, whereas non-normal distributed data were compared by the Mann-Whitney Wilcoxon test. Person test was used to measure correlations between the variables. Chi-square test was used for qualitative data analysis. Performance of the HbA1c test in GDM screening (considering the OGTT as the reference test) was analyzed by the Receiver Operating Characteristic (ROC) curve. A ROC statistics based upon logistic regression analysis considering the covariates "previous history of GDM", "age" and "BMI" in the model were also carried out. Sensitivity and specificity for different HbA1c cut-off points were calculated.

Results
=======

As shown in [table 1](#T1){ref-type="table"}, the age of GDM patients was significantly higher than controls (p \< 0.001). Positive family, as well as previous GDM history were significantly higher in the GDM pregnant mothers than the control group (p = 0.04 and p \< 0.001, respectively). More pregnant women in the GDM group underwent the caesarean section than controls (p = 0.02). Mean of BMI in the GDM group was significantly higher compared with the non-GDM group (p \< 0.001). More participants in the GDM group had history of GDM in previous pregnancies, compared with the controls (p \< 0.001). TG (p \< 0.001), LDL.C (p \< 0.001) and HDL.C (p = 0.001), but not TC were significantly different between the two groups. Significant correlation was shown between HbA1c and neonatal Apgar, as well as HbA1c and neonatal height (p = 0.03 and p = 0.04, respectively). A ROC analysis ([Figure 1](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}) found an AUC of 0.82 (95% CI = 0.734-0.898, p \< 0.001) and the best equilibrium between sensitivity and specificity for HbA1c was 5.05.

###### 

GDM patient's characteristics compared with controls

  **Variables**                               **Control (N = 200)**   **GDM (N = 200)**   **P value** [2](#TFN2){ref-type="table-fn"}   
  ------------------------------------------- ----------------------- ------------------- --------------------------------------------- ----------
  Age (year)[1](#TFN1){ref-type="table-fn"}   26.6 ± 4.7              29.8 ± 4.6          \< 0.001                                      
  Familial history of GDM                     Positive                18 (9%)             40 (20%)                                      0.04
  Negative                                    182 (91%)               160 (80%)                                                         
  Previous GDM                                Positive                7 (3.5%)            22 (11%)                                      \< 0.001
  Negative                                    193 (96.5%)             178 (89%)                                                         
  Complications during pregnancy              Yes                     25 (12%)            12 (6%)                                       0.2
  No                                          175 (78%)               188 (94%)                                                         
  Labor                                       Caesarean               70 (35%)            114 (57%)                                     0.02
  Natural                                     130 (65%)               86 (43%)                                                          
  Gestational age (week)                      27.6 ± 1.7              28.3 ± 2.1          0.58                                          
  BMI (kg/m^2^)                               24.2 ± 4.4              27.4 ± 5.3          \< 0.001                                      
  FPG (mg/dl)                                 85 ± 6.4                97.6 ± 5.1          0.001                                         
  1hPG (mg/dl)                                120.3 ± 15.3            199.8 ± 13.6        \< 0.001                                      
  2hPG (mg/dl)                                106.5 ± 1.8             168.1 ± 2.6         \< 0.001                                      
  HbA1c (%)                                   4.1 ± 0.31              5.5 ± 0.66          \< 0.001                                      
  TC (mg/dl)                                  207.4 ± 42.6            200.7 ± 46.4        0.24                                          
  LDL.C (mg/dl)                               124.8 ± 34.9            104.1 ± 34.4        \< 0.001                                      
  HDL.C (mg/dl)                               68.3 ± 19.5             55.7 ± 11.7         0.001                                         
  TG (mg/dl)                                  177.3 ± 27.8            222.8 ± 82.3        \< 0.001                                      
  Neonate weight (kg)                         3.1 ± 0.4               3.3 ± 0.5           0.1                                           
  Neonate height (cm)                         50 ± 2.2                50.6 ± 2.9          0.2                                           
  Neonate head circumference (cm)             35.8 ± 1.7              35.5 ± 1.5          0.4                                           
  Apgar                                       9.03 ± 0.58             9.01 ± 0.69         0.8                                           

Means ± SE (all such values);

p values were measured by independent sample t-test for quantitative and chi-square test for qualitative data; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglyceride; GDM, gestational diabetes mellitus
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Discussion
==========

According to recent studies, HbA1c value has become globally standardized and been suggested as a simpler, more accurate and automated test for GDM screening ([@B18], [@B19]). However, diagnostic cut-offs reported in different studies are inconsistent ([@B9], [@B10], [@B18], [@B19]).

###### 

HbA1c test performance in GDM diagnosis

  **HbA1c**   **Sensitivity (%)**   **Specificity (%)**
  ----------- --------------------- ---------------------
  4.2500      0.938                 0.00
  4.3500      0.923                 0.031
  4.4500      0.908                 0.062
  4.5500      0.892                 0.2
  4.6500      0.862                 0.323
  4.7500      0.846                 0.415
  4.8500      0.831                 0.554
  4.9500      0.800                 0.692
  5.0500      0.800                 0.76
  5.1500      0.769                 0.8
  5.2500      0.723                 0.877
  5.3500      0.662                 0.954
  5.4500      0.585                 0.969
  5.5500      0.508                 0.969
  5.6500      0.431                 0.985
  5.7500      0.369                 1
  5.8500      0.292                 1
  5.9500      0.262                 1
  6.0500      0.231                 1
  6.1500      0.169                 1
  6.2500      0.108                 1
  6.4000      0.046                 1
  6.5500      0.031                 1

It seems that due to differences among genetic and environmental factors, it is necessary to determine cut-off values for HbA1c in each population. The present study showed that the best cut-off value for HbA1c as a screening tool in Iranian women with GDM is 5.05%. Sensitivity and specificity for HbA1c were 80% and 76%, respectively. The HbA1c cut-off points of 5.3% and 5.4% were reported by WHO 1999 and ADA/WHO 2013 for GDM diagnosis ([@B9], [@B10]). Having said that, sensitivity values for these cut-offs were 68% and 70%, which do not provide robust basis for measure being a standard screening tool. Our results showed that HbA1c values and OGTT in GDM were significantly higher than healthy pregnant women. Age, familial and previous history of GDM, BMI and lipid profile (except total cholesterol) were also significantly different between the two groups. More pregnant women in the GDM group underwent cesarean section. Insulin resistance occurs during pregnancy due to secretion of hormones by the placenta, including growth hormone, corticotropin-releasing hormone, placental lactogen and progesterone. This phenomenon ensures adequate nutrients to the developing fetus ([@B20]). GDM occurs when mother has insufficient insulin to cope increasing need. Due to the OGTT disadvantages for GDM screening, HbA1c was suggested as a screening tool and it should be optimized in each population for determine cut-off values.

In a study done in Indian women, researchers suggested HbA1c ≥ 5.95% as a cut-off value to confirm the diagnosis of GDM ([@B18]). The other study compared OGTT and HbA1c for detecting GDM. Researchers concluded that a cut-off value of ≥ 5.4% had 85.7% sensitivity and 61.1% specificity ([@B21]). In a smaller retrospective study, accuracy of HbA1c in detecting GDM was 87% compared with OGTT. The cut-off value of HbA1c was 6% in the mentioned study ([@B22]). Our study was a case-control study which GDM was diagnosed according to the OGTT. Given that anemia can affect cut-off value of HbA1c, women with anemia was excluded from this study. More patients in the patient group had history of previous GDM. Therefore, it was concluded that the cut-off value of HbA1c in patients with the previous history of GDM is lower than others. Genetic variations lead to differences in HbA1c levels due to variant degree of Hb glycosylation independent of glycaemia ([@B23]). Hence, it is proposed that reference ranges should be established before implementation of HbA1c as a universal screening test for GDM. To our knowledge, there is no study that determines cut-off value for HbA1c in Iranian women with known GDM (diasgnosed via OGTT). It is anticipated that validating simple screening tools such as HbA1c in pregnancy lead to decrease in burden of testing and increase in patient's access and compliance. This would play an important role in the GDM management.

The present study has a few limitations. The most important one was that in this case-control study the causal relationship between variables could not be analyzed. Moreover, participants were from North-west of Iran which may differ from other populations. It is suggested that this study should be done in different ethnic groups in Iran, before the application of HbA1c as a method for GDM screening. In another hand, the present study was done in a referral center of Zanjan. More multi-center studies with larger sample size are needed to consider 5.05% as HbA1c cut-off value for screening of GDM pregnant women in North-west of Iran.

Conclusion
==========

Pregnant women with HbA1c of ≥ 5.05% should be proceed with an OGTT. But more studies with larger sample size are needed to determine the diagnostic and screening value of HbA1c in identifying pregnant women with GDM.
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